FOCUSING on IMPROVING THE LIVES of PATIENTS

WITH DIFFICULT-TO-TREAT DISEASES

OF NOTE

BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

COMBINING the EXPERTISE of our TEAM and our PARTNERS to BREAK THROUGH BARRIERS in EARLY STAGE DRUG DEVELOPMENT